Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Christopher Lieu

Concepts (338)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Colorectal Neoplasms
33
2022
584
7.010
Why?
Molecular Targeted Therapy
9
2019
380
2.420
Why?
Antineoplastic Agents
13
2021
2071
2.340
Why?
Biomarkers, Tumor
14
2022
1045
2.160
Why?
Neoplasms
11
2022
2037
1.470
Why?
Antineoplastic Combined Chemotherapy Protocols
12
2021
1397
1.450
Why?
Drug Resistance, Neoplasm
8
2019
681
1.290
Why?
Vascular Endothelial Growth Factor A
4
2020
517
1.070
Why?
Colonic Neoplasms
4
2021
226
1.070
Why?
Proto-Oncogene Proteins p21(ras)
4
2019
241
1.030
Why?
Bevacizumab
4
2020
124
1.020
Why?
Mutation
11
2020
3447
0.910
Why?
Neuroendocrine Tumors
5
2022
71
0.910
Why?
Antibodies, Monoclonal, Humanized
6
2020
634
0.830
Why?
Age of Onset
7
2022
494
0.800
Why?
Piperidines
2
2017
176
0.750
Why?
Colectomy
1
2019
77
0.740
Why?
Neoplasm Staging
9
2021
1226
0.740
Why?
Early Detection of Cancer
2
2022
304
0.730
Why?
Cetuximab
2
2020
95
0.710
Why?
Cyclosporine
1
2018
186
0.700
Why?
Azetidines
1
2017
38
0.680
Why?
Terminology as Topic
1
2019
229
0.680
Why?
Benzimidazoles
1
2018
147
0.680
Why?
Appendiceal Neoplasms
2
2020
15
0.670
Why?
Microsatellite Instability
5
2021
26
0.650
Why?
Disease-Free Survival
6
2019
682
0.620
Why?
Adrenal Gland Neoplasms
3
2022
74
0.610
Why?
Healthcare Disparities
1
2021
465
0.610
Why?
Patient Rights
1
2015
9
0.590
Why?
MAP Kinase Kinase Kinases
1
2015
71
0.590
Why?
Precision Medicine
1
2019
315
0.590
Why?
Pyrimidinones
1
2015
89
0.590
Why?
Genetic Predisposition to Disease
3
2022
2424
0.590
Why?
Therapies, Investigational
1
2015
16
0.580
Why?
Drug and Narcotic Control
1
2015
30
0.580
Why?
Drugs, Investigational
1
2015
22
0.580
Why?
Pyridones
1
2015
107
0.570
Why?
Humans
66
2022
113846
0.560
Why?
Neovascularization, Pathologic
2
2013
291
0.550
Why?
Rectal Neoplasms
3
2020
102
0.550
Why?
Wnt Signaling Pathway
1
2015
140
0.540
Why?
Pyrazines
2
2018
86
0.530
Why?
Drug Evaluation, Preclinical
1
2013
192
0.500
Why?
Immunoglobulin G
1
2017
798
0.490
Why?
Proto-Oncogene Proteins B-raf
4
2020
205
0.480
Why?
Drug Design
1
2013
177
0.480
Why?
Terminal Care
1
2015
205
0.460
Why?
Carcinoma, Signet Ring Cell
1
2011
3
0.460
Why?
Middle Aged
29
2021
28753
0.460
Why?
Neoplasm Metastasis
7
2022
616
0.450
Why?
ErbB Receptors
4
2017
549
0.440
Why?
Cell Transformation, Neoplastic
1
2013
346
0.440
Why?
Immunotherapy
3
2021
462
0.430
Why?
Fibroblast Growth Factors
1
2011
176
0.410
Why?
Adult
27
2022
31979
0.400
Why?
src-Family Kinases
1
2010
96
0.400
Why?
Stomach Neoplasms
3
2022
74
0.390
Why?
Aged
22
2022
20109
0.380
Why?
Patient Selection
3
2019
694
0.380
Why?
Pancreatic Neoplasms
4
2022
744
0.370
Why?
Boronic Acids
1
2008
44
0.370
Why?
Health Services Accessibility
1
2015
777
0.360
Why?
Etoposide
1
2008
166
0.360
Why?
Medical Oncology
3
2021
189
0.360
Why?
Carboplatin
1
2008
138
0.360
Why?
Disease Management
4
2021
606
0.350
Why?
Adenocarcinoma
3
2021
804
0.350
Why?
Clinical Decision-Making
3
2019
274
0.350
Why?
Genomics
3
2022
626
0.340
Why?
Xenograft Model Antitumor Assays
5
2021
788
0.340
Why?
Shock, Septic
1
2009
190
0.330
Why?
Kaplan-Meier Estimate
6
2017
872
0.330
Why?
Pathology, Molecular
2
2017
26
0.330
Why?
Pathology, Clinical
2
2017
36
0.330
Why?
Drug Administration Schedule
4
2019
825
0.310
Why?
ras Proteins
2
2017
155
0.310
Why?
Male
28
2022
60993
0.310
Why?
Clinical Trials as Topic
3
2015
1009
0.290
Why?
Female
28
2021
63035
0.290
Why?
Age Factors
5
2021
3330
0.280
Why?
Diagnosis, Differential
1
2009
1432
0.280
Why?
Ovarian Neoplasms
2
2020
341
0.280
Why?
Chemotherapy, Adjuvant
3
2021
325
0.270
Why?
United States
12
2021
12329
0.260
Why?
Antibodies, Monoclonal
4
2019
1302
0.260
Why?
Signal Transduction
6
2018
4923
0.240
Why?
Genetic Testing
3
2022
382
0.240
Why?
Disease Models, Animal
4
2021
3910
0.230
Why?
Neoplasms, Multiple Primary
1
2022
52
0.230
Why?
Colorectal Neoplasms, Hereditary Nonpolyposis
1
2022
31
0.230
Why?
Neoadjuvant Therapy
3
2021
288
0.230
Why?
Membrane Proteins
3
2019
1098
0.230
Why?
Pheochromocytoma
1
2022
53
0.220
Why?
Health Status Disparities
2
2020
220
0.220
Why?
Meningioma
1
2022
72
0.220
Why?
Congresses as Topic
2
2019
209
0.210
Why?
Heterografts
1
2021
126
0.210
Why?
Circulating Tumor DNA
1
2020
18
0.210
Why?
Consensus
2
2019
427
0.200
Why?
Practice Patterns, Physicians'
1
2009
1214
0.200
Why?
Treatment Outcome
10
2021
9002
0.200
Why?
Adenomatous Polyposis Coli Protein
1
2019
17
0.200
Why?
Smad4 Protein
1
2019
35
0.200
Why?
Immune System
1
2021
198
0.200
Why?
GTP Phosphohydrolases
1
2019
63
0.200
Why?
Retinal Vein
1
2019
7
0.200
Why?
African Americans
2
2020
1101
0.200
Why?
Area Under Curve
2
2018
328
0.190
Why?
Class I Phosphatidylinositol 3-Kinases
1
2019
74
0.190
Why?
Cell-Free Nucleic Acids
1
2019
23
0.190
Why?
Clinical Trials, Phase II as Topic
1
2019
56
0.190
Why?
Camptothecin
2
2017
87
0.190
Why?
B7-H1 Antigen
1
2020
132
0.190
Why?
Disease Progression
4
2017
2489
0.190
Why?
Survivorship
1
2018
24
0.180
Why?
Survival Rate
5
2021
1854
0.180
Why?
Clinical Trials, Phase III as Topic
1
2018
76
0.180
Why?
Esophageal Neoplasms
1
2021
222
0.180
Why?
Retinal Diseases
1
2019
71
0.180
Why?
Neoplasm Grading
1
2019
252
0.180
Why?
Genes, ras
1
2018
98
0.180
Why?
Vasculitis
1
2019
87
0.180
Why?
Dose-Response Relationship, Drug
2
2017
2229
0.180
Why?
Cohort Studies
6
2020
5011
0.180
Why?
Patient Advocacy
1
2018
68
0.180
Why?
Risk Factors
6
2022
9050
0.180
Why?
Proportional Hazards Models
3
2017
1141
0.180
Why?
Acneiform Eruptions
1
2017
1
0.180
Why?
Asthenia
1
2017
2
0.180
Why?
Neoplasm Transplantation
1
2018
268
0.180
Why?
Incidence
5
2022
2470
0.170
Why?
Drug Eruptions
1
2017
26
0.170
Why?
Hypokalemia
1
2017
32
0.170
Why?
Population Surveillance
1
2021
439
0.170
Why?
Receptor, ErbB-3
1
2017
44
0.170
Why?
Histone Deacetylase Inhibitors
1
2019
201
0.170
Why?
Risk Assessment
2
2019
3147
0.170
Why?
Chemoradiotherapy, Adjuvant
1
2017
37
0.170
Why?
Evidence-Based Medicine
2
2019
728
0.170
Why?
Programmed Cell Death 1 Receptor
1
2019
182
0.170
Why?
MAP Kinase Kinase 1
1
2017
72
0.170
Why?
Imidazoles
1
2018
259
0.170
Why?
Patient Compliance
1
2021
604
0.160
Why?
Antineoplastic Agents, Immunological
1
2019
154
0.160
Why?
Digestive System Neoplasms
1
2016
7
0.160
Why?
Hospitals
1
2021
468
0.160
Why?
Intercellular Signaling Peptides and Proteins
2
2015
378
0.160
Why?
Triple Negative Breast Neoplasms
1
2019
151
0.160
Why?
Insulin-Like Growth Factor I
1
2018
280
0.160
Why?
Aged, 80 and over
7
2021
6796
0.160
Why?
Edema
1
2016
116
0.160
Why?
Diabetic Neuropathies
1
2016
79
0.160
Why?
Biliary Tract Neoplasms
1
2015
22
0.160
Why?
Capecitabine
1
2015
43
0.160
Why?
GPI-Linked Proteins
1
2016
59
0.160
Why?
Databases, Factual
3
2017
1206
0.150
Why?
Prognosis
7
2020
3544
0.150
Why?
Analgesics
1
2016
157
0.150
Why?
Device Approval
1
2015
22
0.150
Why?
Delivery of Health Care, Integrated
1
2018
232
0.150
Why?
Time Factors
2
2019
7060
0.150
Why?
Receptor, Notch1
1
2015
66
0.150
Why?
Cancer Survivors
1
2018
153
0.150
Why?
Patient Care Planning
1
2016
166
0.150
Why?
Tumor Suppressor Protein p53
1
2019
465
0.150
Why?
Prevalence
1
2022
2407
0.150
Why?
Animals
9
2021
35394
0.140
Why?
Neuralgia
1
2016
143
0.140
Why?
Deoxycytidine
1
2015
146
0.140
Why?
Immunoblotting
1
2015
375
0.140
Why?
Pancreas
1
2017
262
0.140
Why?
Health Behavior
1
2020
716
0.140
Why?
Gene Dosage
1
2015
148
0.140
Why?
Drug Approval
1
2015
72
0.140
Why?
Spinal Cord Injuries
1
2016
153
0.140
Why?
Administration, Oral
1
2017
798
0.140
Why?
Immunoconjugates
1
2016
93
0.140
Why?
DNA Copy Number Variations
1
2015
159
0.140
Why?
Liver Neoplasms
1
2018
454
0.140
Why?
Delivery of Health Care
1
2021
695
0.140
Why?
United States Food and Drug Administration
1
2015
179
0.140
Why?
Quinazolines
1
2015
244
0.140
Why?
Phenotype
2
2021
3050
0.140
Why?
Neoplasm Recurrence, Local
1
2019
789
0.130
Why?
Randomized Controlled Trials as Topic
1
2019
1136
0.130
Why?
Genetic Variation
1
2019
991
0.130
Why?
beta Catenin
1
2015
228
0.130
Why?
Oligonucleotide Array Sequence Analysis
1
2015
835
0.130
Why?
Lymphocytes
1
2015
392
0.130
Why?
Registries
1
2021
1824
0.120
Why?
Patient-Centered Care
1
2018
477
0.120
Why?
Proto-Oncogene Proteins
1
2017
716
0.120
Why?
Drug Combinations
1
2013
300
0.120
Why?
Ligands
1
2013
532
0.120
Why?
Cell Line, Tumor
2
2019
2936
0.120
Why?
Protein Kinase Inhibitors
1
2018
858
0.110
Why?
Angiogenesis Inhibitors
1
2013
224
0.110
Why?
Patient Care Team
1
2016
532
0.110
Why?
Risk
1
2014
943
0.110
Why?
Retrospective Studies
6
2021
11340
0.110
Why?
Transcriptome
1
2015
692
0.100
Why?
Streptococcaceae
1
2009
2
0.100
Why?
Protein-Tyrosine Kinases
1
2013
450
0.100
Why?
Clinical Medicine
1
2009
20
0.100
Why?
Patient Satisfaction
1
2013
602
0.100
Why?
Myositis
1
2009
42
0.100
Why?
Cytokines
2
2015
1981
0.090
Why?
Sulindac
1
2008
18
0.090
Why?
Bortezomib
1
2008
49
0.090
Why?
Neutrophils
1
2015
1324
0.090
Why?
Young Adult
3
2020
10971
0.090
Why?
Mutation Rate
2
2019
25
0.090
Why?
Maximum Tolerated Dose
1
2008
187
0.090
Why?
Nausea
1
2008
116
0.090
Why?
Neutropenia
1
2008
133
0.090
Why?
Mice
4
2021
15641
0.090
Why?
Prospective Studies
2
2017
6250
0.090
Why?
Combined Modality Therapy
1
2011
1243
0.090
Why?
Fluphenazine
1
2007
5
0.090
Why?
Risperidone
1
2007
25
0.090
Why?
Leucovorin
2
2021
42
0.090
Why?
Nerve Fibers, Myelinated
1
2007
49
0.080
Why?
Multivariate Analysis
3
2017
1599
0.080
Why?
Anemia
1
2008
166
0.080
Why?
Drug Therapy, Combination
1
2010
1004
0.080
Why?
Fluorouracil
2
2021
139
0.080
Why?
Gastrectomy
2
2017
78
0.080
Why?
Fasting
1
2008
280
0.080
Why?
Food
1
2008
163
0.080
Why?
Thrombocytopenia
1
2008
184
0.080
Why?
Propensity Score
2
2017
226
0.080
Why?
Postoperative Complications
1
2017
2116
0.080
Why?
Frontal Lobe
1
2007
168
0.080
Why?
Antipsychotic Agents
1
2007
198
0.070
Why?
Adolescent
3
2020
18736
0.070
Why?
Survival Analysis
2
2017
1414
0.060
Why?
Oxidative Stress
1
2010
1244
0.060
Why?
Apoptosis
2
2015
2675
0.060
Why?
Receptors, Peptide
1
2022
27
0.060
Why?
Intestinal Neoplasms
1
2022
25
0.060
Why?
Radioisotopes
1
2022
41
0.060
Why?
Gallium Radioisotopes
1
2022
22
0.060
Why?
Radionuclide Imaging
1
2022
159
0.060
Why?
Neoplastic Syndromes, Hereditary
1
2021
28
0.060
Why?
Positron Emission Tomography Computed Tomography
1
2022
72
0.060
Why?
Europe
1
2022
351
0.060
Why?
North America
1
2022
274
0.060
Why?
Chimerism
1
2021
28
0.060
Why?
Preventive Medicine
1
2021
40
0.060
Why?
Canada
1
2022
336
0.060
Why?
Lymphoid Tissue
1
2021
63
0.060
Why?
Lymphocyte Subsets
1
2021
88
0.050
Why?
Liquid Biopsy
1
2020
6
0.050
Why?
National Cancer Institute (U.S.)
1
2020
35
0.050
Why?
Radiopharmaceuticals
1
2022
207
0.050
Why?
Morbidity
1
2021
259
0.050
Why?
Mice, SCID
1
2021
363
0.050
Why?
Neoplasm, Residual
1
2020
84
0.050
Why?
Geography
1
2020
199
0.050
Why?
Positron-Emission Tomography
1
2022
301
0.050
Why?
SEER Program
1
2020
211
0.050
Why?
Mice, Inbred NOD
1
2021
564
0.050
Why?
Receptor Protein-Tyrosine Kinases
1
2022
268
0.050
Why?
Spectrophotometry, Infrared
1
2019
91
0.050
Why?
District of Columbia
1
2018
18
0.050
Why?
Karnofsky Performance Status
1
2018
38
0.050
Why?
DNA Mismatch Repair
1
2018
26
0.050
Why?
Fluorescein Angiography
1
2019
109
0.050
Why?
Colon
1
2020
222
0.050
Why?
Lymphocytes, Tumor-Infiltrating
1
2019
112
0.050
Why?
Multimodal Imaging
1
2019
110
0.040
Why?
Structure-Activity Relationship
1
2019
576
0.040
Why?
Delphi Technique
1
2018
133
0.040
Why?
Tomography, Optical Coherence
1
2019
138
0.040
Why?
Half-Life
1
2017
187
0.040
Why?
American Medical Association
1
2017
20
0.040
Why?
Genomic Instability
1
2017
40
0.040
Why?
Genome, Human
1
2019
394
0.040
Why?
Mice, Nude
1
2019
700
0.040
Why?
Needles
1
2016
56
0.040
Why?
Infusions, Intravenous
1
2017
412
0.040
Why?
Radiotherapy, Adjuvant
1
2017
195
0.040
Why?
Radiotherapy, Intensity-Modulated
1
2017
132
0.040
Why?
Retreatment
1
2016
66
0.040
Why?
Platinum
1
2016
29
0.040
Why?
Health Services Needs and Demand
1
2018
259
0.040
Why?
Molecular Diagnostic Techniques
1
2017
95
0.040
Why?
Incidental Findings
1
2016
81
0.040
Why?
Tumor Microenvironment
1
2019
369
0.040
Why?
Jagged-1 Protein
1
2015
28
0.040
Why?
Serrate-Jagged Proteins
1
2015
30
0.040
Why?
Chemoradiotherapy
1
2017
199
0.040
Why?
Acute Disease
1
2019
1000
0.040
Why?
Neoplasm Invasiveness
1
2017
454
0.040
Why?
DNA Mutational Analysis
1
2017
420
0.040
Why?
Hematopoietic Stem Cell Transplantation
1
2021
575
0.040
Why?
Biomarkers
2
2017
3501
0.040
Why?
Gene Duplication
1
2015
67
0.040
Why?
Gene Frequency
1
2017
572
0.040
Why?
Magnetic Resonance Imaging
1
2007
3049
0.040
Why?
Endoscopy, Digestive System
1
2016
117
0.040
Why?
Protein Isoforms
1
2016
348
0.040
Why?
Preoperative Care
1
2017
339
0.040
Why?
Leukocyte Count
1
2015
325
0.030
Why?
Calcium-Binding Proteins
1
2015
221
0.030
Why?
Mice, Knockout
1
2021
2893
0.030
Why?
CD8-Positive T-Lymphocytes
1
2019
662
0.030
Why?
Brain Neoplasms
1
2021
960
0.030
Why?
Societies, Medical
1
2018
768
0.030
Why?
Radiography
1
2016
828
0.030
Why?
Protein Processing, Post-Translational
1
2016
429
0.030
Why?
Ultraviolet Rays
1
2016
418
0.030
Why?
Analysis of Variance
1
2017
1517
0.030
Why?
Behavior, Animal
1
2016
625
0.030
Why?
Logistic Models
1
2017
2053
0.030
Why?
Skin
1
2016
702
0.030
Why?
Immunohistochemistry
1
2016
1831
0.030
Why?
Follow-Up Studies
1
2020
4906
0.030
Why?
Rats, Sprague-Dawley
1
2016
3027
0.030
Why?
Angiogenesis Inducing Agents
1
2009
24
0.030
Why?
Protein Binding
1
2016
2115
0.030
Why?
Glycogen Synthase Kinase 3 beta
1
2008
59
0.020
Why?
Practice Guidelines as Topic
1
2017
1529
0.020
Why?
Glycogen Synthase Kinase 3
1
2008
85
0.020
Why?
Reference Standards
1
2008
194
0.020
Why?
Quality of Life
1
2018
2136
0.020
Why?
Breast Neoplasms
1
2019
1909
0.020
Why?
Rats
1
2016
6387
0.020
Why?
Pharmacogenetics
1
2008
170
0.020
Why?
Mice, Inbred C57BL
1
2016
5249
0.020
Why?
Chromatography, High Pressure Liquid
1
2008
595
0.020
Why?
Tandem Mass Spectrometry
1
2008
398
0.020
Why?
Tomography, X-Ray Computed
1
2016
2380
0.020
Why?
Predictive Value of Tests
1
2011
2025
0.020
Why?
Reference Values
1
2007
877
0.020
Why?
Image Processing, Computer-Assisted
1
2007
725
0.020
Why?
Longitudinal Studies
1
2007
2692
0.010
Why?
Lieu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2022 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)